Physician profile
Scott Alan Miller
NPI 1306833645
$3,096.53
in general payments reported to CMS, 2019-2025
19 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $92.58 · 2021: $90.47 · 2022: $296 · 2023: $325 · 2024: $396 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Travel and Lodging: $777 · Education: $99.99 · Entertainment: $24.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.86 |
| Travel and Lodging | $776.96 |
| Education | $99.99 |
| Entertainment | $24.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $884.12 | 2025 | |
| Bausch & Lomb Americas INC. | $409.56 | 2022-2025 | Infuse, Biotrue One Day |
| Tarsus Pharmaceuticals, INC. | $251.85 | 2025 | Xdemvy |
| Coopervision INC. | $234.23 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $180.81 | 2022-2024 | Rocklatan |
| Johnson & Johnson Vision Care, INC. | $167.82 | 2021-2024 | Acuvue |
| Dompe US, INC. | $151.72 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $142.92 | 2024 | Acthar |
| Optos, INC. | $127.08 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $101.33 | 2019 | |
| Glaukos Corporation | $100.03 | 2025 | Idosetr |
| Abbvie INC. | $94.85 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $81.12 | 2019-2021 | |
| Lombart Brothers, INC. | $45.80 | 2024 | Opd-III |
| Aerie Pharmaceuticals, INC. | $30.75 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $27.22 | 2024 | |
| Horizon Therapeutics Plc | $26.58 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $23.69 | 2022 | |
| Amgen INC. | $15.05 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.